Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
PALO ALTO, Calif., July 20, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases announced today the European Commission (EC) has granted marketing authorization for Zokinvy® (lonafarnib), a first-in-class breakthrough therapy for children and young adults with Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL).
Collectively known as progeria, HGPS and PL are devastating ultra-rare, and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. Without Zokinvy treatment, children with HGPS die at an average age of 14.5 years.3,4 "Until now, no medication has been approved in Europe for people living with this debilitating condition. For the first time we have a therapeutic option with Zokinvy which has been proven to meaningfully extend the average life span of children with HGPS by nearly one third," said Professor Thorsten Marquardt, Paediatric and Adolescent Medicine, University of Münster, Germany. "With less than 5% of rare diseases having an approved treatment, the authorization of Zokinvy represents both a significant medical milestone and increased hope for the progeria community." The EC authorization follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 which was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72%, and extended life by an average of 4.3 years in children and young adults with HGPS.2 "The European Commission's approval of Zokinvy, Eiger's first approval in Europe, is the culmination of years of dedication and commitment by the Eiger team and the Progeria Research Foundation, our partners in this pioneering endeavor," said David Cory, President and CEO, Eiger. "Eiger's mission is to bring innovative medicines to underserved patients around the world. We are proud of this approval which further demonstrates our ability to partner with investigators and regulators to achieve that mission." "The approval of Zokinvy is extremely welcome news for families and the entire progeria community," added Marjet Stamsnijder, President, Progeria Family Circle. "I am delighted we now have a treatment approved for use in Europe that has the ability to transform the lives of children and young adults with progeria." The European Commission's centralized marketing authorization is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway. Regulatory review is ongoing by the UK's Medicine and Healthcare products Regulatory Agency (MHRA) as part of the European Commission Decision Reliance Procedure. Eiger expects to make Zokinvy available following successful completion of reimbursement discussions country-by-country. About progeria
Collectively known as progeria, Hutchinson-Gilford progeria syndrome and progeroid laminopathies are ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients. There are approximately 20 children and young adults with progeria identified across Europe. HGPS is caused by a point mutation in the LMNA gene, yielding the farnesylated aberrant protein, progerin. Progeroid laminopathies are genetic conditions of accelerated aging caused by a constellation of mutations in the LMNA and/or ZMPSTE24 genes yielding farnesylated proteins that are distinct from progerin.4,5 Without Zokinvy therapy, children with HGPS commonly die of the same heart disease that affects millions of normally aging adults (arteriosclerosis), by an average age of 14.5 years. Disease manifestations include severe failure to thrive, scleroderma–like skin, global lipodystrophy, alopecia, joint contractures, skeletal dysplasia, global accelerated atherosclerosis with cardiovascular decline, and debilitating strokes.3 About Zokinvy® (lonafarnib)
Zokinvy is a first-in-class disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins which leads to cellular instability and premature aging in children and young adults with progeria. Zokinvy has demonstrated a statistically significant survival benefit in children and young adults with HGPS.1,4 The most commonly reported adverse reactions were gastrointestinal (vomiting, diarrhea, nausea), and most were mild or moderate (Grade 1 or 2) in severity. Many progeria patients have received continuous Zokinvy therapy for more than 10 years.1,2 Eiger licensed exclusive worldwide rights to Zokinvy from Merck, known as MSD, outside of the United States and Canada. Merck will not receive any milestone payments for the development of Zokinvy for the treatment of progeria and has waived royalty obligations from Eiger for a specified quantity of Zokinvy. Zokinvy EU indication
In Europe, Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation. For the labeled safety information for Zokinvy please see the full European Summary of Product Characteristics here. For Important Safety Information and prescribing information for Zokinvy in the U.S., please visit www.zokinvy.com. About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from TOGETHER, a Phase 3 investigator-initiated study. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. About Progeria Family Circle
The Progeria Family Circle (PFC) is a European patient network, founded in 1997, supporting children and young adults with progeria and their families on a European level. The PFC goal is to support better and faster recognition of symptoms of progeria, raise awareness for a better acceptance of progeria children and young adults in public communities, provide opportunities for families to meet each other through many annual reunions throughout Europe, and offer other necessary and permanent support for families with children with progeria. For more information, please visit www.progeriafamilycircle.blogspot.com. Forward-looking statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and objectives for future operations, are forward looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the timing of our ongoing and planned clinical development across our pipeline and the potential for success of any of our products or product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the "Risk Factors" sections in the Annual Report on Form 10-Q for the quarter ended March 31, 2022 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise. CONTACTS: Investors: Media: References:
SOURCE Eiger BioPharmaceuticals, Inc. |
||
Company Codes: NASDAQ-NMS:EIGR |
View original content to download multimedia: